

Gonzalo Laje

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8504188/publications.pdf>

Version: 2024-02-01

51
papers

7,078
citations

117625

34
h-index

189892

50
g-index

54
all docs

54
docs citations

54
times ranked

9701
citing authors

#	ARTICLE	IF	CITATIONS
1	Using polygenic scores and clinical data for bipolar disorder patient stratification and lithium response prediction: machine learning approach. <i>British Journal of Psychiatry</i> , 2022, 220, 219-228.	2.8	11
2	Association of polygenic score for major depression with response to lithium in patients with bipolar disorder. <i>Molecular Psychiatry</i> , 2021, 26, 2457-2470.	7.9	44
3	Association of Attention-Deficit/Hyperactivity Disorder and Depression Polygenic Scores with Lithium Response: A Consortium for Lithium Genetics Study. <i>Complex Psychiatry</i> , 2021, 7, 80-89.	0.9	6
4	Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients. <i>Translational Psychiatry</i> , 2021, 11, 606.	4.8	25
5	Investigating polygenic burden in age at disease onset in bipolar disorder: Findings from an international multicentric study. <i>Bipolar Disorders</i> , 2019, 21, 68-75.	1.9	20
6	Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder. <i>JAMA Psychiatry</i> , 2018, 75, 65-74.	11.0	102
7	Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder. <i>Frontiers in Psychiatry</i> , 2018, 9, 207.	2.6	28
8	Delayed diagnosis in a house of correction: Smith's Magenis syndrome due to a de novo nonsense <i>RAI1</i> variant. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 2383-2388.	1.2	4
9	Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. <i>Human Molecular Genetics</i> , 2016, 25, 3383-3394.	2.9	182
10	Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. <i>Lancet, The</i> , 2016, 387, 1085-1093.	13.7	306
11	A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks. <i>British Journal of Pharmacology</i> , 2014, 171, 2230-2242.	5.4	61
12	National Trends in the Mental Health Care of Children, Adolescents, and Adults by Office-Based Physicians. <i>JAMA Psychiatry</i> , 2014, 71, 81.	11.0	368
13	The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. <i>Brain Imaging and Behavior</i> , 2014, 8, 153-182.	2.1	696
14	RNA-sequencing of the brain transcriptome implicates dysregulation of neuroplasticity, circadian rhythms and GTPase binding in bipolar disorder. <i>Molecular Psychiatry</i> , 2014, 19, 1179-1185.	7.9	100
15	Race, Genetic Ancestry and Response to Antidepressant Treatment for Major Depression. <i>Neuropsychopharmacology</i> , 2013, 38, 2598-2606.	5.4	39
16	RETENTION AND ATTRITION AMONG AFRICAN AMERICANS IN THE STAR*D STUDY: WHAT CAUSES RESEARCH VOLUNTEERS TO STAY OR STRAY?. <i>Depression and Anxiety</i> , 2013, 30, 1137-1144.	4.1	17
17	Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies. <i>American Journal of Psychiatry</i> , 2013, 170, 207-217.	7.2	216
18	Pharmacogenetics of mood disorders: what clinicians need to know. <i>CNS Spectrums</i> , 2013, 18, 272-284.	1.2	11

#	ARTICLE	IF	CITATIONS
19	Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. PLoS ONE, 2013, 8, e65636.	2.5	156
20	Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. Journal of Psychopharmacology, 2012, 26, 360-367.	4.0	36
21	Identification of common variants associated with human hippocampal and intracranial volumes. Nature Genetics, 2012, 44, 552-561.	21.4	594
22	Relationship of Ketamine's Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression. Biological Psychiatry, 2012, 72, 331-338.	1.3	230
23	Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients. Biological Psychiatry, 2012, 72, e27-e28.	1.3	187
24	The Bcl-2 Gene Polymorphism rs956572AA Increases Inositol 1,4,5-Trisphosphate Receptor-Mediated Endoplasmic Reticulum Calcium Release in Subjects with Bipolar Disorder. Biological Psychiatry, 2011, 69, 344-352.	1.3	65
25	Genome-wide association studies of antidepressant outcome: A brief review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1553-1557.	4.8	41
26	A functional alternative splicing mutation in human tryptophan hydroxylase-2. Molecular Psychiatry, 2011, 16, 1169-1176.	7.9	21
27	A non-synonymous polymorphism in galactose mutarotase (GALM) is associated with serotonin transporter binding potential in the human thalamus: results of a genome-wide association study. Molecular Psychiatry, 2011, 16, 584-585.	7.9	19
28	Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. International Journal of Neuropsychopharmacology, 2010, 13, 715-724.	2.1	35
29	Autism spectrum features in Smith-Magenis syndrome. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2010, 154C, 456-462.	1.6	92
30	Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2010, 154C, 463-468.	1.6	24
31	The International Consortium on Lithium Genetics (ConLiGen): An Initiative by the NIMH and IGSLI to Study the Genetic Basis of Response to Lithium Treatment. Neuropsychobiology, 2010, 62, 72-78.	1.9	134
32	Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. International Journal of Neuropsychopharmacology, 2010, 13, 93.	2.1	104
33	Pharmacogenetics Studies in STAR*D: Strengths, Limitations, and Results. Psychiatric Services, 2009, 60, 1446-1457.	2.0	69
34	Genetic and Clinical Predictors of Sexual Dysfunction in Citalopram-Treated Depressed Patients. Neuropsychopharmacology, 2009, 34, 1819-1828.	5.4	88
35	The DISC locus and schizophrenia: evidence from an association study in a central European sample and from a meta-analysis across different European populations. Human Molecular Genetics, 2009, 18, 2719-2727.	2.9	78
36	Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenetics and Genomics, 2009, 19, 666-674.	1.5	103

#	ARTICLE	IF	CITATIONS
37	Association study of phosphodiesterase genes in the Sequenced Treatment Alternatives to Relieve Depression sample. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 235-238.	1.5	29
38	Pharmacogenetics Studies in STAR*D: Strengths, Limitations, and Results. <i>Psychiatric Services</i> , 2009, 60, 1446-57.	2.0	50
39	The FKBP5-Gene in Depression and Treatment Response—An Association Study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. <i>Biological Psychiatry</i> , 2008, 63, 1103-1110.	1.3	240
40	Genetic Markers of Suicidal Ideation Emerging During Citalopram Treatment of Major Depression. <i>Focus (American Psychiatric Publishing)</i> , 2008, 6, 69-79.	0.8	3
41	Genetic Markers of Suicidal Ideation Emerging During Citalopram Treatment of Major Depression. <i>American Journal of Psychiatry</i> , 2007, 164, 1530-1538.	7.2	203
42	National Trends in the Outpatient Diagnosis and Treatment of Bipolar Disorder in Youth. <i>Archives of General Psychiatry</i> , 2007, 64, 1032.	12.3	595
43	Association of GRIK4 With Outcome of Antidepressant Treatment in the STAR*D Cohort. <i>American Journal of Psychiatry</i> , 2007, 164, 1181-1188.	7.2	189
44	Association Between a Functional Serotonin Transporter Promoter Polymorphism and Citalopram Treatment in Adult Outpatients With Major Depression. <i>Archives of General Psychiatry</i> , 2007, 64, 783.	12.3	208
45	Three-year medication prophylaxis in panic disorder: to continue or discontinue? A naturalistic study. <i>Comprehensive Psychiatry</i> , 2007, 48, 419-425.	3.1	19
46	The Pharmacogenetics of Major Depression: Past, Present, and Future. <i>Biological Psychiatry</i> , 2007, 62, 1205-1207.	1.3	26
47	Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant Treatment. <i>American Journal of Human Genetics</i> , 2006, 78, 804-814.	6.2	434
48	National Trends in the Outpatient Treatment of Children and Adolescents With Antipsychotic Drugs. <i>Archives of General Psychiatry</i> , 2006, 63, 679.	12.3	540
49	Trends in the Treatment of Bipolar Disorder by Outpatient Psychiatrists. <i>American Journal of Psychiatry</i> , 2002, 159, 1005-1010.	7.2	180
50	HYPOCHONDRIASIS AND ITS RELATIONSHIP TO OBSESSIVE-COMPULSIVE DISORDER. <i>Psychiatric Clinics of North America</i> , 2000, 23, 605-616.	1.3	49
51	Pharmacogenetics and mood disorders. , 0, , 368-379.		0